Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment

BACKGROUND AND AIM: Several reports have demonstrated that skeletal muscle mass influences mortality in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment; however, there is still controversy with regard to whether skeletal muscle and adipose tissue are associated with the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Koji, Saitho, Yoshinori, Hayashi, Hidemi, Hasebe, Takumu, Nakajima, Shunsuke, Ikuta, Katsuya, Fujiya, Mikihiro, Okumura, Toshikatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684515/
https://www.ncbi.nlm.nih.gov/pubmed/31406927
http://dx.doi.org/10.1002/jgh3.12167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684515/
https://www.ncbi.nlm.nih.gov/pubmed/31406927
http://dx.doi.org/10.1002/jgh3.12167

Ejemplares similares